[HTML][HTML] Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK …
X Zhang, S Zhang, X Yang, J Yang, Q Zhou, L Yin… - Molecular cancer, 2010 - Springer
Background The anaplastic lymphoma kinase (ALK) gene is frequently involved in translocations
that lead to gene fusions in a variety of human malignancies, including lymphoma and …
that lead to gene fusions in a variety of human malignancies, including lymphoma and …
[HTML][HTML] Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma
…, YL Wu, S Thongprasert, CH Yang… - … England Journal of …, 2009 - Mass Medical Soc
Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods In …
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods In …
[HTML][HTML] Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation …
W Zhong, X Yang, H Yan, X Zhang, J Su… - Journal of Hematology & …, 2015 - Springer
Background Neoadjuvant erlotinib and customized adjuvant therapy are appealing but
controversial. The purpose of this study was to evaluate the role of biomarker-guided …
controversial. The purpose of this study was to evaluate the role of biomarker-guided …
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
…, HJ Chen, YL Sun, Q Zhou, JJ Yang, XN Yang… - Clinical cancer …, 2017 - AACR
Purpose: Although clinical studies have shown promise for targeting programmed cell death
protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the …
protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the …
Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer
W Zhong, X Yang, J Bai, J Yang… - European journal of …, 2008 - academic.oup.com
There is a great deal of concern about metastasis of lung cancer to regional lymph nodes, due
partly to the work of groups of thoracic surgeons in Japan and North America beginning in …
partly to the work of groups of thoracic surgeons in Japan and North America beginning in …
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib …
…, SW Kim, JJ Yang, MJ Ahn, J Wang, JCH Yang… - The Lancet …, 2015 - thelancet.com
Background Optimum management strategies for patients with advanced non-small-cell lung
cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined…
cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined…
[HTML][HTML] Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 …
…, HT Ma, JJ Yang, HH Yan, XN Yang… - Journal of clinical …, 2021 - ncbi.nlm.nih.gov
METHODS From September 2011 to April 2014, 222 patients from 27 sites were randomly
assigned 1: 1 to adjuvant gefitinib (n= 111) or VP (n= 111). Patients with resected stage II-IIIA (…
assigned 1: 1 to adjuvant gefitinib (n= 111) or VP (n= 111). Patients with resected stage II-IIIA (…
Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer
…, RQ Liao, S Dong, Y Guan, P Dai, XC Zhang, JJ Yang… - Cancer Discovery, 2022 - AACR
This study confirms the prognostic value of MRD detection in patients with NSCLC after definitive
surgery, especially in those with longitudinal undetectable MRD, which might represent …
surgery, especially in those with longitudinal undetectable MRD, which might represent …
[PDF][PDF] Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non–small-cell lung cancer
Purpose Approximately 1% to 2% of non–small-cell lung cancers (NSCLCs) harbor a c-ros
oncogene 1 (ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic lymphoma kinase (…
oncogene 1 (ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic lymphoma kinase (…
[PDF][PDF] Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer
Q Zhou, XC Zhang, ZH Chen, XL Yin, JJ Yang… - J Clin …, 2011 - gdghospital.org.cn
… Zhi-Hong Chen Collection and assembly of data: Zhi-Hong Chen, Jin-Ji Yang, Chong-Rui
Xu, Hua-Jun Chen, Jian Su, Wen-Zhao Zhong, Xue-Ning Yang, Bin-Chao Wang, Yi-Sheng …
Xu, Hua-Jun Chen, Jian Su, Wen-Zhao Zhong, Xue-Ning Yang, Bin-Chao Wang, Yi-Sheng …